BIBLIOGRAFÍA


- AGA Technical review on non-alcoholic fatty liver disease. Gastroenterology 2002;123:1705-1725.


- Chalasani N. Statins and hepatotoxicity: focus on patients with fatty liver. Hepatology 2005;41:690-695.


- Cohen DE, Anania FA, Chalasani N. An assessment of statin safety by hepatologists. Am J Cardiol 2006;97[suppl]:77C-81C.


- García-Ruiz C, Colell A, Morales A, Kaplowitz N, Fernandez-Checa JC. Role of oxidative stress generated from the mitochondrial electron transport chain and mitochondrial glutathiome status in loss of mitochondrial function and activation of transcription factor nuclear


- Kogiso T, Moriyoshi Y, Nagahara H. Clinical Significance of high sensitivity c-reactive protein (hs-CRP) in non-alcoholic fatty liver disease (NAFLD. J Hepatol 2006;44 (SuppS2):S256,

- Kok N, Roberfroid M, Delzenne N. Dietary oligofructose modifies the impact of fructose on hepatic triacylglycerol metabolism. Metabolism 1996;45:1547-1550.


- Law MR, Rudnicka AR. Statin safety: evidence from the published literature. Am J Cardiol 2006;97(suppl 8A):52C-60C.


- Naoumova RP, Marais AD, Mountney J, Frith JC, Rendel NB, Taylor GW, Thomson GR. Plasma mevalonic acid, an index of cholesterol synthesis in vivo, and responsiveness to HMG-CoA reductase...


- National Cholesterol Education Program. Third report of the expert panel on detection, evaluation, and treatment of high cholesterol in adults (Adult Treatment Panel III).


- Neuschwander-Tetri BA, Brunt EM, Wehmeier KR, Oliver D, Bacon BR. Improved nonalcoholic steatohepatitis after 48 weeks of treatment
with the PPAR-gamma ligand rosiglitazone. Hepatology 2003;38:1008-17.


- Ong JP, Younossi ZM. Nonalcoholic fatty liver disease (NAFLD) two decades later: are we smarter about its natural history? Am J Gastroenterol 2003;98:1915-1917.


- Perez-Carrera M, Del Hoya P, Ma M, Rubio J, Martín A. Activity of the mitochondrial respiratory chain enzymes is decreased in the liver of patients respiratory chain enzymes is decreased in the liver of patients with non-alcoholic steatohepatitis. Hepatology 1999;30:379A.


- Rappaport AM, Borowy ZJ, Lougheed WM, Lotto WN. Subdivision of hexagonal liver lobules into a structural and functional unit; role in hepatic physiology and pathology. Anat Rec 1954;119:11.


- Reid AE. Nonalcoholic steatohepatitis. Gastroenterology 2001; 121:710-723.


- Saadeh S, Younossi ZM, Remer EM, Gramlich T, Ong JP, Hurley M, Mullen KD, Cooper JN, Sheridan MJ. The utility of radiological imaging
in non-alcoholic fatty liver disease. Gastroenterology 2002;123:745-750.


- Saksena S. Natural history and determinants of disease progression in non-alcoholic fatty liver disease: good and bad news. Hepatology 2003;38:232A


- Smith CC, Bernstein LI, Davis RB, Rind DM, Shmerling RH. Screening for statin-related toxicity: The yield of transaminase and creatine kinase

- Sniderman AD. Is there value in liver function test and creatine phosphokinase monitoring for statin use?. Am J Cardiol 2004;94(suppl):30F-34F.


- Willis RA, Fulkers K, Tucker JL, Ye C-Q, Xia L-J, Tamagawa H. Lovastatin decreases coenzyme Q levels in rats Proc Natl Acad Sci USA 1990; 87: 8928-8930


- Yamamoto A, Hoshi K, Ichihara K. Fluvastatin, an inhibitor of 3-hydroxy-3-methylglutaryl-CoA reductase, scavenges free radicals and


